HC Wainwright Reiterates “$6.00” Price Target for Sophiris Bio (SPHS)

HC Wainwright set a $6.00 target price on Sophiris Bio (NASDAQ:SPHS) in a research report report published on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Maxim Group set a $5.00 target price on shares of Sophiris Bio and gave the stock a buy rating in a research note on Thursday, March 22nd. ValuEngine raised shares of Sophiris Bio from a sell rating to a hold rating in a research note on Tuesday, May 1st.

Shares of SPHS opened at $3.36 on Tuesday. Sophiris Bio has a fifty-two week low of $3.51 and a fifty-two week high of $3.68. The company has a market cap of $105.69 million, a P/E ratio of -8.40 and a beta of 1.29. The company has a current ratio of 5.90, a quick ratio of 9.94 and a debt-to-equity ratio of 1.30.

Sophiris Bio (NASDAQ:SPHS) last announced its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. research analysts forecast that Sophiris Bio will post -0.57 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new stake in shares of Sophiris Bio in the 4th quarter valued at approximately $453,000. Goldman Sachs Group Inc. purchased a new stake in shares of Sophiris Bio in the 4th quarter valued at approximately $312,000. Finally, Virtu Financial LLC increased its position in shares of Sophiris Bio by 389.7% in the 4th quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 135,119 shares during the last quarter. 6.43% of the stock is currently owned by institutional investors.

About Sophiris Bio

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply